- Home
- JNJ vs ABBV Comparison
JNJ vs ABBV Comparison
Compare JNJ & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNJ
- ABBV
- Stock Information
- Founded
- JNJ 1886
- ABBV 2012
- Country
- JNJ United States
- ABBV United States
- Employees
- JNJ N/A
- ABBV N/A
- Industry
- JNJ Biotechnology: Pharmaceutical Preparations
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- JNJ Health Care
- ABBV Health Care
- Exchange
- JNJ Nasdaq
- ABBV Nasdaq
- Market Cap
- JNJ 370.9B
- ABBV 329.1B
- IPO Year
- JNJ 1944
- ABBV N/A
- Fundamental
- Price
- JNJ $151.30
- ABBV $183.99
- Analyst Decision
- JNJ Buy
- ABBV Buy
- Analyst Count
- JNJ 16
- ABBV 23
- Target Price
- JNJ $169.33
- ABBV $211.55
- AVG Volume (30 Days)
- JNJ 7.8M
- ABBV 8.2M
- Earning Date
- JNJ 04-15-2025
- ABBV 04-25-2025
- Dividend Yield
- JNJ 3.44%
- ABBV 3.57%
- EPS Growth
- JNJ N/A
- ABBV N/A
- EPS
- JNJ 8.98
- ABBV 2.34
- Revenue
- JNJ $89,331,000,000.00
- ABBV $57,367,000,000.00
- Revenue This Year
- JNJ $3.87
- ABBV $8.53
- Revenue Next Year
- JNJ $4.15
- ABBV $8.14
- P/E Ratio
- JNJ $16.84
- ABBV $78.55
- Revenue Growth
- JNJ 4.30
- ABBV 5.45
- 52 Week Low
- JNJ $140.68
- ABBV $153.58
- 52 Week High
- JNJ $169.99
- ABBV $218.66
- Technical
- Relative Strength Index (RSI)
- JNJ 44.31
- ABBV 46.63
- Support Level
- JNJ $146.12
- ABBV $176.57
- Resistance Level
- JNJ $157.94
- ABBV $192.69
- Average True Range (ATR)
- JNJ 2.62
- ABBV 6.06
- MACD
- JNJ -0.50
- ABBV -0.31
- Stochastic Oscillator
- JNJ 42.88
- ABBV 33.11
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).